Trulicity clinical trials
Pro Research Analysisby 
Searched over 200M research papers
Dulaglutide (Trulicity) Clinical Trials: Efficacy and Safety in Type 2 Diabetes
Efficacy of Dulaglutide in Glycemic Control and Weight Reduction
Clinical trials have shown that dulaglutide (Trulicity), a once-weekly GLP-1 receptor agonist, is effective in improving glycemic control in adults with type 2 diabetes. In the AWARD program, dulaglutide demonstrated greater glucose-lowering effects compared to metformin, sitagliptin, exenatide, and insulin glargine, and was non-inferior to liraglutide 1.8 mg once daily 123. When used as monotherapy, dulaglutide was more effective than oral metformin and noninferior to liraglutide in reducing HbA1c at 26 weeks . In combination with other agents, dulaglutide outperformed sitagliptin, exenatide, and insulin glargine in improving glycemic control over 26 to 104 weeks .
Dulaglutide 1.5 mg once weekly, but not the 0.75 mg dose, consistently reduced body weight from baseline, and these benefits were maintained for up to two years 24.
Safety and Tolerability of Dulaglutide
Dulaglutide has been generally well tolerated in clinical trials, with a low risk of hypoglycemia 24. The most common side effects were gastrointestinal, such as nausea, vomiting, and diarrhea . In a pharmacokinetic study comparing dulaglutide to a biosimilar (HEC14028), both drugs showed similar safety profiles, with no serious adverse events or increased immunogenicity .
Cardiovascular Outcomes and Use in High-Risk Populations
The REWIND cardiovascular outcomes trial found that dulaglutide significantly reduced the risk of major adverse cardiac events (MACE), including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, over a median follow-up of 5.4 years in patients with or without existing cardiovascular disease . Dulaglutide was also effective and well tolerated in high-risk groups, such as obese and elderly patients, and those with chronic kidney disease or cardiovascular disease .
Clinical Use and Reimbursement
Dulaglutide is approved as an adjunct to diet and exercise for adults with type 2 diabetes and is reimbursed in some countries after failure of dual oral therapy with metformin and a sulfonylurea or pioglitazone 13. Its once-weekly dosing offers convenience for patients 24.
Conclusion
Dulaglutide (Trulicity) has demonstrated strong efficacy in glycemic control and weight reduction, with a favorable safety profile and cardiovascular benefits in adults with type 2 diabetes. Its once-weekly administration and effectiveness in diverse patient populations make it a valuable option for diabetes management 1234+1 MORE.
Sources and full results
Most relevant research papers on this topic